Ipsen: operating margin improves in first half
(CercleFinance.com) - Ipsen has published H1 diluted EPS that is up 18.
5% at 3.38 euros, with an operating margin that is up 1.2 percentage point at 31.5%, despite the dilutive impact of the acquisition of Clementia.
The pharmaceutical company's revenues reached 1,229.6 million euros, up 14.3% in organic terms, including specialty medicine sales that are up 16.9%, driven by oncology (+20.7%), while family health sales fell by 3.7%.
Ipsen has raised its 2019 targets, targeting sales growth of over 14% in organic terms, with an operating margin of approximately 30% (including the impact of Clementia, although excluding additional growth investments in its R&D portfolio).
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
5% at 3.38 euros, with an operating margin that is up 1.2 percentage point at 31.5%, despite the dilutive impact of the acquisition of Clementia.
The pharmaceutical company's revenues reached 1,229.6 million euros, up 14.3% in organic terms, including specialty medicine sales that are up 16.9%, driven by oncology (+20.7%), while family health sales fell by 3.7%.
Ipsen has raised its 2019 targets, targeting sales growth of over 14% in organic terms, with an operating margin of approximately 30% (including the impact of Clementia, although excluding additional growth investments in its R&D portfolio).
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.